{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:57:24Z","timestamp":1793739444927,"version":"4.6.1"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bone is among the main sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life. Despite the success of immunotherapies in oncology, no immunotherapies are approved for bone metastasis and no clear benefit has been observed with approved immunotherapies in treatment of bone metastatic disease. Therefore, it is crucial to consider unique features of tumor microenvironment in bone metastasis when developing novel therapies. The vicious cycle of bone metastasis, referring to crosstalk between tumor and bone cells that enables the tumor cells to grow in the bone microenvironment, is a well-established concept. Very recently, a novel osteoimmuno-oncology (OIO) concept was introduced to the scientific community. OIO emphasizes the significance of interactions between tumor, immune and bone cells in promoting tumor growth in bone metastasis, and it can be used to reveal the most promising targets for bone metastasis. In order to provide an insight into the current immuno-oncology drug development landscape, we used 1stOncology database, a cancer drug development resource to identify novel immunotherapies in preclinical or clinical development for breast and prostate cancer bone metastasis. Based on the database search, 24 immunotherapies were identified in preclinical or clinical development that included evaluation of effects on bone metastasis. This review provides an insight to novel immuno-oncology drug development in the context of bone metastasis. Bone metastases can be approached using different modalities, and tumor microenvironment in bone provides many potential targets for bone metastasis. Noting current increasing interest in the field of OIO, more therapeutic opportunities that primarily target bone metastasis are expected in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1121878","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T15:06:16Z","timestamp":1688569576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Insights into immuno-oncology drug development landscape with focus on bone metastasis"],"prefix":"10.3389","volume":"14","author":[{"given":"Tiina E.","family":"K\u00e4hk\u00f6nen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi M.","family":"Halleen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"MacRitchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie M.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Bernoulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016022","article-title":"Survival after bone metastasis by primary cancer type: a Danish population-based cohort study","volume":"7","author":"Svensson","year":"2017","journal-title":"BMJ Open"},{"key":"B3","article-title":"Skeletal-related adverse events during bone metastasis of breast cancer: current status","volume":"27","author":"Yang","year":"2019","journal-title":"Discovery Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040999","article-title":"The contribution of the immune system in bone metastasis pathogenesis","volume":"20","author":"Xiang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-20301-6_7","article-title":"Bone metastasis of breast cancer","volume":"1152","author":"Tahara","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molimm.2017.11.023","article-title":"Beyond the vicious cycle: the role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis","volume":"110","author":"Owen","year":"2019","journal-title":"Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116014","article-title":"CD8+ T cells from experimental in situ breast carcinoma interfere with bone homeostasis","volume":"150","author":"Monteiro","year":"2021","journal-title":"Bone"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061529","article-title":"Osteoimmuno-oncology: therapeutic opportunities for targeting immune cells in bone metastasis","volume":"10","author":"K\u00e4hk\u00f6nen","year":"2021","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","article-title":"Novel approaches to target the microenvironment of bone metastasis","volume":"18","author":"Hofbauer","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","first-page":"1797","article-title":"Translational research of PT-112, a clinical agent in advanced phase I development: evident bone tropism, synergy In vitro with bortezomib and lenalidomide , and potent efficacy in the Vk*MYC mouse model of multiple myeloma","volume":"130","author":"Ames","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.83","article-title":"PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: findings from two phase I studies","volume":"38","author":"Bryce","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101430","article-title":"Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours","volume":"49","author":"Karp","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e17025","article-title":"A phase 1b study of novel immunogenic cell death inducer PT-112 plus PD-L1 inhibitor avelumab in metastatic castrate-resistant prostate cancer (mCRPC) patients","volume":"39","author":"Bryce","year":"2021","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of p-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B22","doi-asserted-by":"crossref","first-page":"Abstract 5203","DOI":"10.1158\/1538-7445.AM2020-5203","article-title":"MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3, exhibits immunomodulatory activity and enhanced antitumor activity in combination with checkpoint inhibitors","volume":"80","author":"Scribner","year":"2020","journal-title":"Cancer Research"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc702","article-title":"620P - MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion","volume":"32","author":"Shenderov","year":"2021","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12935-018-0614-z","article-title":"Clinical significance of serum soluble B7-H3 in patients with osteosarcoma","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070689","article-title":"B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405259101","article-title":"The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization","volume":"101","author":"Suh","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.05.013","article-title":"Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblasts","volume":"216","author":"Xu","year":"2011","journal-title":"Immunobiology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.087","article-title":"DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1\/2 multicenter study","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0945","article-title":"Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer","volume":"26","author":"Kyriakopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004198","article-title":"Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)","volume":"10","author":"McNeel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40425-019-0516-1","article-title":"FLT PET\/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab","volume":"7","author":"Scarpelli","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2021.0094","article-title":"Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology","volume":"74","author":"Lasek","year":"2021","journal-title":"Cent Eur J Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/15353702221089910","article-title":"Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1\/TGF\u03b2RII agent: current status","volume":"247","author":"Gameiro","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101322","article-title":"NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models","volume":"16","author":"Xu","year":"2022","journal-title":"Transl Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0249","article-title":"Phase I study of the bifunctional fusion protein bintrafusp Alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort","volume":"25","author":"Doi","year":"2020","journal-title":"Oncologist"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.08.004","article-title":"TGF-\u03b2 in cancer and bone: implications for treatment of bone metastases","volume":"48","author":"Ju\u00e1rez","year":"2011","journal-title":"Bone"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0407","article-title":"Preliminary safety, pharmacokinetics\/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors","volume":"8","author":"Shum","year":"2020","journal-title":"JITC"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S65802","article-title":"Tremelimumab: research and clinical development","volume":"9","author":"Comin-Anduix","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9067","article-title":"Treatment with or without chemotherapy in high-risk, stage IVA\/B NSCLC","volume":"40","author":"Leitzel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4564","article-title":"Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study","volume":"40","author":"Stecca","year":"2022","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"crossref","first-page":"Abstract 4551","DOI":"10.1158\/1538-7445.AM2020-4551","article-title":"Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index","volume":"80","author":"Engelhardt","year":"2020","journal-title":"Cancer Research"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc1058","article-title":"740P - anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 \u00b1 nivolumab (NIVO) in patients (pts) with advanced cancers: updated phase I results","volume":"33","author":"Gutierrez","year":"2022","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1634\/theoncologist.2019-0932","article-title":"Phase I trial of a modified vaccinia Ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors","volume":"25","author":"Collins","year":"2020","journal-title":"Oncologist"},{"key":"B51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-018-0409-8","article-title":"Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer","volume":"6","author":"Redman","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"crossref","first-page":"Abstract 616MO","DOI":"10.1016\/j.annonc.2020.08.875","article-title":"Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)","volume":"31","author":"Redman","year":"2020","journal-title":"Annals of Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.582","article-title":"582 immune correlates from QuEST1 in men with castration-resistant prostate cancer","volume":"9","author":"Toney","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human phase I study of the oral inhibitor of indoleamine 2,3-Dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"crossref","first-page":"Abstract 5026","DOI":"10.1158\/1538-7445.AM2020-5026","article-title":"Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer","volume":"80","author":"K\u00e4hk\u00f6nen","year":"2020","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.9.1459","article-title":"Talabostat","volume":"16","author":"Cunningham","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc702","article-title":"BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): phase II results","volume":"32","author":"Monk","year":"2021","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.01.007","article-title":"Therapeutic effects of mesenchymal stem cells loaded with oncolytic adenovirus carrying decorin on a breast cancer lung metastatic mouse model","volume":"24","author":"Zhang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.219","article-title":"Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients","volume":"36","author":"Westdorp","year":"2018","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz253","article-title":"1523 - natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"30","author":"Creemers","year":"2019","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"Abstract 224","DOI":"10.1136\/jitc-2021-SITC2021.224","article-title":"M2 macrophage-mediated immune suppression of chimeric antigen receptor T cells via PD-L1 signaling in prostate cancer","volume":"9","author":"Yamaguchi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.091","article-title":"Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Dorff","year":"2022","journal-title":"J Clin Oncol"},{"key":"B65","article-title":"Drug evaluation: reolysin\u2013wild-type reovirus as a cancer therapeutic","volume":"8","author":"Stoeckel","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4538-4","article-title":"A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian cancer trials group IND.213","volume":"167","author":"Bernstein","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9279-8","article-title":"Intravenous administration of reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors","volume":"28","author":"Gollamudi","year":"2010","journal-title":"Invest New Drugs"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24263","article-title":"A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209","volume":"9","author":"Eigl","year":"2018","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12985-021-01630-z","article-title":"Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis","volume":"18","author":"Xie","year":"2021","journal-title":"Virol J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0283-2","article-title":"Mycobacterial immunotherapy for prostate cancer: where can we go from here","volume":"17","author":"Stavrinides","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3892\/ol.2022.13367","article-title":"The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: a case report of six patients","volume":"24","author":"Dalgleish","year":"2022","journal-title":"Oncol Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.125","article-title":"BXCL701: first-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype\u2013phase 2a results","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.098","article-title":"Systemic delivery of an oncolytic adenovirus expressing decorin for the treatment of breast cancer bone metastases","volume":"26","author":"Yang","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv Cancer Res"},{"key":"B75","doi-asserted-by":"crossref","first-page":"Abstract 2649","DOI":"10.1158\/1538-7445.AM2022-2649","article-title":"Orally bioavailable small molecule CXCR4 antagonists with enhanced efficacy in mouse models of genitourinary cancers","volume":"82","author":"Miller","year":"2022","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1277","article-title":"STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to eradicate genetically distinct castration-resistant prostate cancers","volume":"24","author":"Moreira","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur Urol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s40610-019-0114-5","article-title":"Novel and conventional preclinical models to investigate bone metastasis","volume":"5","author":"K\u00e4hk\u00f6nen","year":"2019","journal-title":"Curr Mol Bio Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061615","article-title":"Immunotherapies and metastatic cancers: understanding utility and predictivity of human immune cell engrafted mice in preclinical drug development","volume":"12","author":"K\u00e4hk\u00f6nen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/9781119535331.ch6","article-title":"Preclinical osteoimmuno-oncology models to study effects of immunotherapies on bone metastasis","volume-title":"Animal Models for the Development of Cancer Immunotherapy","author":"K\u00e4hk\u00f6nen","year":"2022"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211022881","article-title":"Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer","volume":"13","author":"Lin","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15063","article-title":"Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: a real-world multi-institutional study","volume":"28","author":"Yamamichi","year":"2022","journal-title":"Int J Urol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.1382","article-title":"1382 DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers","volume":"10","author":"Shi","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"B85","doi-asserted-by":"crossref","first-page":"Abstract 2870","DOI":"10.1158\/1538-7445.AM2021-2870","article-title":"Limited data from clinical trials assessing immunotherapy effects on bone metastases","volume":"81","author":"K\u00e4hk\u00f6nen","year":"2021","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121878\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T15:06:26Z","timestamp":1688569586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121878\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2023.1121878"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1121878","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"article-number":"1121878"}}